PetIQ EBITDA 2011-2026 | PETQ

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA PetIQ

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
81.6 M	15.3 M	55.2 M	27.8 M	20.7 M	23.5 M	16.9 M	4.78 M	6.71 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
81.6 M	4.78 M	28 M

Quarterly EBITDA PetIQ

2023-Q3	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
20.2 M	-	-38.9 M	29 M	18.4 M	-	25.8 M	36.9 M	19.5 M	-	15.6 M	14.9 M	5.93 M	-12.6 M	6.64 M	15 M	7.96 M	-4.85 M	15.8 M	14.6 M	-704 K	42 K	4.5 M	8.36 M	5.65 M	116 K	1.1 M	659 K	1.71 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
36.9 M	-38.9 M	8.13 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Drug manufacturers industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
AcelRx Pharmaceuticals ACRX	-13.5 M	-	7.5 %	$ 6.35 M	USA
Alimera Sciences ALIM	6.82 M	-	-	$ 142 M	USA
Aerie Pharmaceuticals AERI	-40 M	-	-	$ 754 M	USA
Agile Therapeutics AGRX	-19.8 M	-	10.11 %	$ 58.2 M	USA
Adamis Pharmaceuticals Corporation ADMP	-23.6 M	-	0.86 %	$ 117 M	USA
Eagle Pharmaceuticals EGRX	81.6 M	-	-39.89 %	$ 27.7 M	USA
Aurora Cannabis ACB	-283 M	$ 3.44	3.46 %	$ 86.3 M	Canada
Harrow Health HROW	31.8 M	$ 36.73	4.35 %	$ 1.35 B	USA
Catalent CTLT	-260 M	-	-	$ 11.5 B	USA
Athenex ATNX	-65.5 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	-39.7 M	-	-	$ 2.06 B	France
Cronos Group CRON	-176 M	$ 2.65	2.62 %	$ 1.39 B	Canada
DURECT Corporation DRRX	-36.9 M	-	-	$ 50.1 M	USA
Emergent BioSolutions EBS	-601 M	$ 8.18	2.12 %	$ 419 M	USA
Endo International plc ENDP	306 M	-	-	$ 28.9 M	Irlanda
Evoke Pharma EVOK	-7.43 M	-	-	$ 36.6 M	USA
Calliditas Therapeutics AB (publ) CALT	-524 M	-	-0.1 %	$ 2.03 B	Schweden
HEXO Corp. HEXO	-85.5 M	-	2.45 %	$ 38.1 M	Canada
Cumberland Pharmaceuticals CPIX	3.06 M	$ 3.34	6.71 %	$ 47 M	USA
Neoleukin Therapeutics NLTX	-100 M	-	-	$ 193 M	Canada
Bausch Health Companies BHC	2.23 B	$ 5.09	2.0 %	$ 1.86 B	Canada
OptiNose OPTN	-22.3 M	-	-	$ 1.08 B	USA
PLx Pharma PLXP	-40.7 M	-	-27.8 %	$ 2.56 M	USA
ProPhase Labs PRPH	28.3 M	-	-	$ 5.07 M	USA
Perrigo Company plc PRGO	-785 M	$ 9.65	0.1 %	$ 1.34 B	USA
Pacira BioSciences PCRX	5.41 M	$ 23.36	0.69 %	$ 1.08 B	USA
Evolus EOLS	-25.2 M	$ 4.35	-1.85 %	$ 280 M	USA
Rockwell Medical RMTI	-5.23 M	$ 1.06	2.65 %	$ 24.7 M	USA
Radius Health RDUS	-53.2 M	-	-	$ 1.42 B	USA
Solid Biosciences SLDB	-178 M	$ 7.24	8.38 %	$ 634 M	USA
Sundial Growers SNDL	-132 M	$ 1.37	-	$ 3.37 M	Canada
Sonoma Pharmaceuticals SNOA	-3.57 M	$ 2.3	-1.71 %	$ 2.85 M	USA
Relmada Therapeutics RLMD	-59.1 M	$ 6.63	8.61 %	$ 262 M	USA
Tilray TLRY	-1.37 B	$ 6.95	4.35 %	$ 4.29 B	Canada
OrganiGram Holdings OGI	-91.8 M	$ 1.39	3.36 %	$ 402 M	Canada
SCYNEXIS SCYX	-16.1 M	$ 0.88	-2.2 %	$ 43.9 M	USA
Veru VERU	-36.6 M	$ 2.31	0.66 %	$ 312 M	USA
Jupiter Wellness JUPW	429 K	-	-	$ 33.6 M	USA
Viatris VTRS	3.51 B	$ 13.58	1.65 %	$ 16.3 B	USA
China Pharma Holdings CPHI	-1.97 M	$ 0.6	6.3 %	$ 10.5 M	China
cbdMD YCBD	-2.86 M	$ 0.77	0.52 %	$ 3.32 M	USA
Assertio Holdings ASRT	8.47 M	$ 18.45	11.75 %	$ 118 M	USA
Lannett Company LCI	-142 M	-	1.15 %	$ 7.11 M	USA
Organogenesis Holdings ORGO	12.3 M	$ 2.44	1.04 %	$ 321 M	USA
Canopy Growth Corporation CGC	-95.6 M	$ 0.98	2.14 %	$ 105 M	Canada
TherapeuticsMD TXMD	-7.6 M	$ 2.33	1.53 %	$ 24.3 M	USA
Recro Pharma REPH	4.65 M	-	-4.76 %	$ 65.3 M	USA
Tricida TCDA	-153 M	-	-	$ 3.25 M	USA
Zynerba Pharmaceuticals ZYNE	-35 M	-	-	$ 55.5 M	USA